ANGO Financials

Income Statement
MetricQ4 2026Q3 2026Q2 2026Q1 2026Q4 2025
Revenue
86.6M
+10.4%
78.4M
-1.3%
79.4M
+4.9%
75.7M
-5.5%
80.2M
Cost of Revenue
39.8M
+7.8%
36.9M
+6.6%
34.6M
+2.4%
33.9M
-10.8%
37.9M
Gross Profit
46.8M
+12.8%
41.5M
-7.4%
44.8M
+7.0%
41.9M
-0.9%
42.2M
Operating Expenses
57.0M
+4.7%
54.4M
+6.9%
50.9M
-3.1%
52.5M
+10.0%
47.7M
R&D
8.2M
+15.4%
7.1M
-8.8%
7.8M
+21.1%
6.4M
-2.6%
6.6M
SG&A
41.4M
+8.5%
38.2M
+3.5%
36.9M
-9.4%
40.7M
+10.9%
36.7M
Operating Income
-10195000
+21.3%
-12951000
-111.4%
-6125000
+42.5%
-10656000
-93.2%
-5516000
EBITDA
-17513000
-1989.9%
-838000
-121.7%
-378000
+91.8%
-4636000
+64.7%
-13148000
Net Income
-11405000
-41.1%
-8084000
-27.3%
-6350000
+41.8%
-10903000
-80.2%
-6050000
EPS (Basic)
$-0.27
-42.1%
$-0.19
-26.7%
$-0.15
+42.3%
$-0.26
-73.3%
$-0.15
EPS (Diluted)
$-0.27
-42.1%
$-0.19
-26.7%
$-0.15
+42.3%
$-0.26
-73.3%
$-0.15
Shares (Diluted)
41.8M
+0.5%
41.6M
+0.1%
41.5M
+0.9%
41.2M
+0.5%
41.0M
AngioDynamics (ANGO) โ€” Financials